Technical Analysis for RCUS - Arcus Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Inside Day | Range Contraction | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Low | Weakness | -0.79% | |
| Below Lower BB | Weakness | -0.79% | |
| Down 3 Days in a Row | Weakness | -0.79% | |
| Gapped Down | Weakness | -0.79% |
| Alert | Time |
|---|---|
| Down 2 % | about 5 hours ago |
| 60 Minute Opening Range Breakdown | about 6 hours ago |
| Possible Inside Day | about 7 hours ago |
| Lower Bollinger Band Support | about 10 hours ago |
| Down 1% | about 11 hours ago |
Get a Trading Sidekick!
- Earnings date: 02/19/2025
Arcus Biosciences, Inc. Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Clinical Development Cancer Treatment Cancer Immunotherapy Monoclonal Antibodies Immunotherapies Adenosine Cd73 Pd 1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 20.31 |
| 52 Week Low | 13.51 |
| Average Volume | 702,195 |
| 200-Day Moving Average | 16.03 |
| 50-Day Moving Average | 15.74 |
| 20-Day Moving Average | 15.24 |
| 10-Day Moving Average | 14.70 |
| Average True Range | 0.75 |
| RSI (14) | 33.33 |
| ADX | 19.01 |
| +DI | 12.99 |
| -DI | 28.30 |
| Chandelier Exit (Long, 3 ATRs) | 15.81 |
| Chandelier Exit (Short, 3 ATRs) | 15.77 |
| Upper Bollinger Bands | 16.64 |
| Lower Bollinger Band | 13.84 |
| Percent B (%b) | -0.01 |
| BandWidth | 18.37 |
| MACD Line | -0.52 |
| MACD Signal Line | -0.36 |
| MACD Histogram | -0.1584 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 14.56 | ||||
| Resistance 3 (R3) | 14.58 | 14.35 | 14.43 | ||
| Resistance 2 (R2) | 14.35 | 14.17 | 14.34 | 14.39 | |
| Resistance 1 (R1) | 14.09 | 14.05 | 13.98 | 14.07 | 14.35 |
| Pivot Point | 13.86 | 13.86 | 13.81 | 13.85 | 13.86 |
| Support 1 (S1) | 13.60 | 13.68 | 13.49 | 13.58 | 13.29 |
| Support 2 (S2) | 13.37 | 13.56 | 13.36 | 13.25 | |
| Support 3 (S3) | 13.11 | 13.37 | 13.21 | ||
| Support 4 (S4) | 13.09 |
